|Bid||11.39 x 800|
|Ask||11.40 x 900|
|Day's Range||11.02 - 11.52|
|52 Week Range||9.76 - 23.50|
|Beta (5Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 15, 2021 - Mar 19, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.60|
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patient’s own hematopoietic stem cells, genetically modified to express cystinosin, the protein that is deficient in patients with cystinosis. AVR-RD-04 is currently being evaluated in a Phase 1/2 clinical trial (NCT03897361) sponsored by AVROBIO’s academic collaborator at the University of California, San Diego.1
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences.
Avrobio Inc (NASDAQ: AVRO) has reported positive data from the ongoing Phase 2 FAB-GTi Phase 1/2 trial evaluating AVR-RD-01, an ex vivo lentiviral gene therapy for Fabry disease. 100% reduction, or complete clearance, of the toxic substrate in the kidney biopsy, was observed in the first patient dosed. The company also announced six-month data from the first patient dosed in the Phase 1/2 trial of AVR-RD-02, an ex vivo lentiviral gene therapy for Gaucher disease type 1, showing substantial improvement over pre-gene therapy enzyme replacement therapy baseline in key biomarkers at six months post-gene therapy. Plasma chitotriosidase levels decreased 49%, and toxic metabolite lyso-Gb1 levels dropped 44% in the first patient at six months post-gene therapy, compared to the patient's pre-gene therapy ERT baseline levels. Additionally, preliminary data from the investigator-sponsored Phase 1/2 trial of AVR-RD-04 showed that all three cystinosis patients demonstrated strong data across multiple measures, including substantial improvement in photophobia in the first patient 12 months post-gene therapy. All patients remained off cysteamine pills, and eye drops, with trial enrollment completion expected this year. The Investor and analyst presentation is scheduled today at 8 a.m. ET. Price Action: AVRO jumped 19.6% at $20.46 in premarket trading on the last check Monday. See more from BenzingaClick here for options trades from BenzingaWell Health Scoops Up CRH Medical For Per Share; CRHM Shares SkyrocketNanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.